ArticleGastroenterology report2026
Phenotypic and genotypic characterization of DGAT1 deficiency in pediatric patients with congenital diarrhea and enteropathy.
Article in Gastroenterology report, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diacylglycerol O-acyltransferase 1 (DGAT1) deficiency is a rare autosomal recessive disorder that disrupts intestinal triglyceride metabolism, leading to congenital diarrhea and enteropathy. This study aimed to characterize the phenotypic and genotypic spectrum of DGAT1 deficiency, evaluate the genotype-phenotype correlations, and assess outcomes following nutritional interventions. Methods: We retrospectively analyzed 12 pediatric patients with DGAT1 deficiency diagnosed between 2016 and 2025. Clinical data, genetic profiles, management, and outcomes were collected. Whole-exome sequencing with Sanger validation was performed, and pathogenicity was classified according to the American College of Medical Genetics and Genomics criteria. A systematic review identified 58 previously reported patients. Kaplan-Meier survival analysis evaluated survival, and Fisher's exact test assessed associations between specific genetic variants and treatment responses. Results: Among 70 patients, 84.3% presented in the neonatal period. The most frequent symptoms were diarrhea (90.0%), vomiting (81.4%), and failure to thrive (84.3%), with hypoalbuminemia observed in 87.1%. Splice-site variants were most prevalent (37.2%) with distinct ethnic distributions. Homozygous variants, especially missense mutations, were associated with more severe manifestations and poorer survival compared with compound heterozygous or splice-site variants ( Conclusions: DGAT1 deficiency typically presents with early-onset refractory diarrhea and nutritional complications. Early genetic testing and prompt initiation of a fat-restricted diet within the first 2 years of life markedly improve survival and long-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.